Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: A multicenter phase 2 trial (AGO-GYN5)

International Journal of Gynecological Cancer

Volumn 24, Issue 2, 2014, Pages 260-265

  Emons, Günter ^a   Gorchev, Grigor ^b   Harter, Philipp ^c   Wimberger, Pauline ^d   Stähle, Anne ^e   Hanker, Lars ^f   Hilpert, Felix ^g   Beckmann, Matthias W ^h   Dall, Peter ⁱ   Gründker, Carsten ^a   Sindermann, Herbert ^j   Sehouli, Jalid ^k  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b University Hospital Dr Georgi Stransky   (Bulgaria)

^c KLINIKEN ESSEN MITTE   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Klinik für Gynäkologieu Geburtshilfe   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁱ Hospital of Luneburg   (Germany)

^j Aeterna Zentaris GmbH   (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Clinical trial; Endometrial cancer; LHRH receptor; Phase 2; Targeted therapy

Indexed keywords

ANTHRACYCLINE; GONADORELIN RECEPTOR; ZOPTARELIN DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BRONCHITIS; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ERYTHEMA; FATIGUE; FEMALE; HOT FLUSH; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRAM EVALUATION; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, LHRH;

EID: 84893797792     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000044     Document Type: Article

References (20)

1. ECO, European Cancer Observatory. International Agency for Research on Cancer. Available at: http://eu-cancer.iarc.fr. Accessed March 25, 2013.
2. American Cancer Society: Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society Inc; 2013.
3. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009;16:38-45.
4. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409-420.
5. Carey MS, Gawlik C, Fung-Kee-Fung M, et al. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol. 2006;101:158-167.
6. Kokka F, Brockbank E, Oram D, et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010;12:CD007926.
7. Emons G, Ortmann O, Schulz KD, et al. Growth-inhibitory actions of analogues of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab. 1997;8:355-362.
8. Bajo AM, Schally AV, Halmos G, et al. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res. 2003;9:3742-3748.
9. Halmos G, Nagy A, Lamharzi N, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett. 1999;136:129-136.
10. Szepeshazi K, Schally AV, Nagy A. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs. Breast Cancer Res Treat. 1999;56:267-276.
11. Westphalen S, Kotulla G, Kaiser F, et al. Receptor-mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol. 2000;17:1063-1069.
12. Emons G, Sindermann H, Engel J, et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology. 2009;90:15-18.
13. Grundker C, Volker P, Griesinger F, et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol. 2002;187:528-537.
14. Emons G, Kaufmann M, Gorchev G, et al. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol. 2010;119:457-461.
15. Föst C, Duwe F, Hellriegel M, et al. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep. 2011;25:1481-1487.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
17. Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Stat Med. 1998;17:2301-2312.
18. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159-2166.
19. Johnson N, Bryant A, Miles T, et al. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev. 2011;10:CD003175.
20. Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261-271.